Jul 16, 2012 - Health + Traits

Leveraging The Direct-to-Patient Research Model in Rheumatoid Arthritis

Janssen Healthcare Innovation, a unit of Janssen Research & Development, LLC, is sponsoring a study in rheumatoid arthritis patients that will be conducted by MediGuard.org (a subsidiary of Quintiles) and 23andMe.

The study, called TogetherRA, will enroll approximately 1,000 patients who are currently receiving or have previously received anti-TNF-alpha therapeutics for their rheumatoid arthritis. MediGuard.org will recruit patients directly out of its 2.7 million member patient community and, with patients’ consent, will gather information related to patients’ diagnosis and response to treatment from medical records.

23andMe will be responsible for genotyping patients, collecting patient-reported outcomes data, integrating medical record data, as well as conducting a genome-wide analysis that will explore genetics and patients’ response to anti-TNF-alpha therapeutics. Notably, all participants in this study will receive access to their own genetic data. 23andMe is excited to conduct this important research in rheumatoid arthritis.

Janssen Healthcare Innovation is sponsoring this study as part of its initiative to explore a direct-to-patient research model and utilize novel ways to conduct research and support an empowered patient experience.

Related Stories

Stay in the know.

Receive the latest from your DNA community.